ReportLinker Reveals Key Insights About Players and Coverage in Latest Combination Vaccine Market Analysis
LYON, France, March 26, 2024 /PRNewswire/ — Reportlinker announces the release of the report “A White Paper To Understand The
Read MoreLYON, France, March 26, 2024 /PRNewswire/ — Reportlinker announces the release of the report “A White Paper To Understand The
Read MoreA large Phase 3 trial will evaluate whether the M72/AS01E vaccine candidate can protect adolescents and adults from pulmonary tuberculosis
Read MoreNew strategic partnership will scale-up manufacturing capacity to support global supply of dengue vaccine and expands Takeda’s footprint in vaccine manufacturing.
Read MoreGAITHERSBURG, Md., Nov. 28, 2023 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-Mâ„¢ adjuvant, today
Read MoreAlbumedix Ltd (‘Albumedix’), now part of the life science group Sartorius, announces that Recombumin® is critical to the manufacture of
Read MoreThis Emergency Use Authorization and CDC recommendation makes Novavax’s vaccine the only protein-based non-mRNA COVID vaccine option in the U.S. Novavax
Read MoreTB is one of the world’s deadliest diseases, killing about 4,300 people per day, mostly those living in poverty LONDON
Read MoreCHENGDU, China, June 9, 2023 /PRNewswire/ — On June 8th, 2023, Coviccine® Trivalent XBB.1.5-Recombinant COVID-19 Trivalent (XBB.1.5+BA.5+Delta) Protein Vaccine (Sf9
Read More87% of respondents deemed mRNA a key modality for the future More than 60% vaccine makers surveyed plan revamp or
Read MoreCHENGDU, China, May 18, 2023 /PRNewswire/ — On May 17, 2023, Recombinant bivalent COVID-19 protein vaccine (Sf9 cells) and recombinant
Read More